ARTICLE | Clinical News

Omega interferon: Phase II

November 19, 2001 8:00 AM UTC

Interim results of an open-label, dose-escalation European trial of omega interferon in 51 patients with previously untreated chronic HCV showed that the product reduced serum HCV RNA levels to undetectable in 45% of patients with genotype 1 HCV and 77% of patients with genotype 2, 3, or 4 strains. The trial has enrolled 90 patients in 6 dosing groups. ...